Abstract
In clinical proteomics, reproducible feature selection is unattainable given the standard statistical hypothesis-testing framework. This leads to irreproducible signatures with no diagnostic power. Instability stems from high P-value variability (p_var), which is inevitable and insolvable. The impact of p_var can be reduced via power increment, for example increasing sample size and measurement accuracy. However, these are not realistic solutions in practice. Instead, workarounds using existing data such as signal boosting transformation techniques and network-based statistical testing is more practical. Furthermore, it is useful to consider other metrics alongside P-values including confidence intervals, effect sizes and cross-validation accuracies to make informed inferences.
Original language | English |
---|---|
Pages (from-to) | 912-918 |
Number of pages | 7 |
Journal | Drug Discovery Today |
Volume | 22 |
Issue number | 6 |
DOIs | |
Publication status | Published - Jun 2017 |
Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2016 Elsevier Ltd
ASJC Scopus Subject Areas
- Pharmacology
- Drug Discovery